Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Drug pricing is emerging as a key challenge for Novo Nordisk, the world's biggest insulin producer, whose previously unstoppable growth has started to flag, according to the Danish firm's chief executive.
Lars Sorensen is certain of one thing: the number of potential customers for his products is going to keep on rising as a global obesity epidemic tips more people into type 2 diabetes in the West and many developing nations.
But he has a mounting fight on his hands when it comes to securing a good price for insulin and other diabetes treatments from cost-conscious reimbursement authorities around the world.
http://uk.reuters.com/article/2013/11/05/us-novonordisk-ceo-idUKBRE9A40I220131105
Lars Sorensen is certain of one thing: the number of potential customers for his products is going to keep on rising as a global obesity epidemic tips more people into type 2 diabetes in the West and many developing nations.
But he has a mounting fight on his hands when it comes to securing a good price for insulin and other diabetes treatments from cost-conscious reimbursement authorities around the world.
http://uk.reuters.com/article/2013/11/05/us-novonordisk-ceo-idUKBRE9A40I220131105